logo-loader
CelLBxHealth PLC

CelLBxHealth PLC - Board changes - Replacement

RNS Number : 8294A
CelLBxHealth PLC
16 April 2026
 

GENERAL TEXT AMENDMENT

 

The following amendment has been made to the 'Board changes' announcement released on 12 January 2026 at 7:00 a.m. under RNS No 4265O.

 

Addition of "Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital." 

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

CelLBxHealth plc (the "Company")

 

Board changes

 

Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect:

 

·      Peter Collins as Chief Executive Officer

·      Klaas de Boer as Non-Executive Director

·      Kim Oreskovic as Non-Executive Director

·      Benjamin Hart as Non-Executive Director

 

The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.

 

Separately Non-Executive Director, Joseph Eid will step down from the board, effective 31 January 2026.

 

Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and the non-executives to the board.   Their extensive expertise, combined with additional life sciences experience will significantly enhance the board's capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future."

 

For further information:

 

CelLBxHealth plc

Peter Collins, Chief Executive Officer

+44 (0) 1483 343434  

investor@CelLBxHealth.com

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

 

+44 (0) 20 7220 0500

 FTI Consulting

Simon Conway, Ciara Martin, Sam Purewal

+44 (0) 203 727 1000

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

About CelLBxHealth plc

 

CelLBxHealth plc is a leading CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

 

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.

 

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

 

For more information, visit https://cellbxhealth.com/.

 

AIM Rules Schedule 2 (g) information

 

The directorships and partnerships currently held by Peter Michael Collins, aged 67, and over the five years preceding the date of this announcement are as follows:

 

Current directorships

Previous directorships held in the past five years

 

Saga Diagnostics UK Limited

SAGA Diagnostics AB

Collins Biotech Consulting SRL

 

The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

Tsjukemar Ltd

General Fusion Inc

Xeros Technology Group plc

SmartKem Inc

Smartkem Ltd

Fashion for Good BV

Entrepreneurs Fund Management LLP

Entrepreneurs Fund Management Services Ltd

veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH)

Stichting Administratiekantoor Bellevue

 

Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital. 

 

The directorships and partnerships currently held by Benjamin Jacob Hart, aged 38, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

 

Applied Technology Partners LLC

 

The directorships and partnerships currently held by Kimberley Anne Oreskovic, aged 60, and over the five years preceding the date of this announcement are as follows:

 

Current directorships         

Previous directorships held in the past five years

Innoviance Investments B.V.

Innoviance Consulting B.V.

 

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASFDFMMEMSEFL
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

5 min read